Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1986 Jul;22(3):191–196. doi: 10.1007/BF00200032

A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state

Saburo Sone 1,, Teruhiro Utsugi 1, Priti Tandon 1, Mitsumasa Ogawara 1
PMCID: PMC11038367  PMID: 3731204

Abstract

Studies were performed on the activation of human blood monocytes to the antitumor state by a dried preparation of multilamellar vesicle (MLV) liposomes in which synthetic muramyl tripeptide phosphatidylethanolamine (MTP-PE) was inserted directly into the liposome membrane. Dried liposomes composed of synthetic phospholipids [phosphatidylcholine (PC) and phosphatidylserine (PS) in a molar ratio of 7:3] were prepared by lyophilization. Dried liposome-MTP-PE was found to be superior in several ways to free desmethyl muramyl dipeptide (norMDP) or conventional liposome-MTP-PE, prepared immediately before use. First, dried lipsome-MTP-PE was stable and strongly activated monocytes when stored for over 3 months in a freezer at −°C or even in suspension at 4°C. Second, human monocytes in suspension, as well as in the adherent form, were activated to the tumoricidal state by interaction for at least 4 h with the dried preparation of liposome-MTP-PE. Third, monocytes activated with the dried liposome-MTP-PE or conventionally prepared liposome-MTP-PE maintained their tumoricidal activity for a longer period (4 days) than those activated with free norMDP. These results indicate that the dried preparation of liposome-MTP-PE can be stored for a long time, has a reproducible effect that can be standardized and should be valuable for in situ activation of human monocytes to the tumoricidal state, which is associated with eradication of cancer metastases.

Keywords: Cancer Research, Phosphatidylcholine, Dipeptide, Cancer Metastasis, Phosphatidylethanolamine

References

  • 1.Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 1982;42:5084. [PubMed] [Google Scholar]
  • 2.Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res. 1980;140:4460. [PubMed] [Google Scholar]
  • 3.Fidler IJ, Raz A, Fogler WE, Hoyer LC, Poste G. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Res. 1981;41:495. [PubMed] [Google Scholar]
  • 4.Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA. 1981;78:1680. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay V, Gisler RH, Schroit AJ. Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod. 1982;1:43. [Google Scholar]
  • 6.Fidler IJ, Barnes ZL, Fogler WE, Kirsh R, Bugelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of established metastases following intravenous injection of macrophage activators. Cancer Res. 1982;42:496. [PubMed] [Google Scholar]
  • 7.Hibbs JB., Jr Role of activated macrophages in nonspecific resistance to neoplasia. J Reticuloendothel Soc. 1976;20:233. [PubMed] [Google Scholar]
  • 8.Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst. 1982;69:1189. [PubMed] [Google Scholar]
  • 9.Kleinerman ES, Erickson KI, Schroit A, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing muramyl tripeptide. Cancer Res. 1983;43:2010. [PubMed] [Google Scholar]
  • 10.Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Ivest. 1983;72:304. doi: 10.1172/JCI110970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh ER. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983;130:1500. [PubMed] [Google Scholar]
  • 12.Phillips NV, Moras ML, Chedid L, Lefrancier P, Bernard JM. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985;45:128. [PubMed] [Google Scholar]
  • 13.Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980;283:139. doi: 10.1038/283139a0. [DOI] [PubMed] [Google Scholar]
  • 14.Poste G, Kirsh R, Fogler WE, Fidler IJ. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res. 1979;39:881. [PubMed] [Google Scholar]
  • 15.Saiki I, Fidler IJ. Synergism between muramyl dipeptide and gamma interferon for activation of mouse alveolar macrophages. J Immunol. 1985;135:2022. [PubMed] [Google Scholar]
  • 16.Saiki S, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJ. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res. 1985;45:6188. [PubMed] [Google Scholar]
  • 17.Schroit AJ, Fidler IJ. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 1982;42:161. [PubMed] [Google Scholar]
  • 18.Sone S, Fidler IJ. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol. 1980;125:2454. [PubMed] [Google Scholar]
  • 19.Sone S, Fidler IJ. In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol. 1981;57:42. doi: 10.1016/0008-8749(81)90118-0. [DOI] [PubMed] [Google Scholar]
  • 20.Sone S, Fidler IJ. Activation of rat alveolar macrophages to the tumoricidal state in the presence of progressively growing pulmonary metastases. Cancer Res. 1981;42:2401. [PubMed] [Google Scholar]
  • 21.Sone S, Tsubura E. Human alveolar macrophages: Potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol. 1982;129:1313. [PubMed] [Google Scholar]
  • 22.Sone S, Poste G, Fidler IJ. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. J Immunol. 1980;24:2197. [PubMed] [Google Scholar]
  • 23.Sone S, Mutsuura S, Ogawara M, Tsubura E. Manipulation of host defense mechanisms. Tokyo: Excerpta Medica; 1983. Stimulatory effect of lipophilic muramyl dipeptide analog encapsulated in liposomes on the tumoricidal activity of human peripheral blood monocytes; p. 28. [Google Scholar]
  • 24.Sone S, Tachibana K, Shono M, Ogushi F, Tsubura E. Potential value of liposomes containing muramyl dipeptide for augmenting the tumoricidal activity of human alveolar macrophages. J Biol Response Mod. 1983;3:185. [PubMed] [Google Scholar]
  • 25.Sone S, Mutsuura S, Ogawara M, Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J Immunol. 1984;132:2105. [PubMed] [Google Scholar]
  • 26.Sone S, Mutsuura S, Ogawara M, Utsugi T, Tsubura E. Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state. Cancer Immunol Immunother. 1984;18:169. doi: 10.1007/BF00205507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sone S, Lopez-Berestein G, Fidler IJ. Kinetics and function of tumor cytotoxic factor(s) produced by human blood monocytes activated to the tumoricidal state. J Natl Cancer Inst. 1985;74:583. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES